Monthly Archives: October 2012

1 10, 2012
  • Permalink Gallery

    Bioavailability study of a polyphenol-enriched extract from Hibiscus sabdariffa in rats and associated antioxidant status

Bioavailability study of a polyphenol-enriched extract from Hibiscus sabdariffa in rats and associated antioxidant status

By |October 1st, 2012|Publicacions|0 Comments|

Fernández-Arroyo S, Herranz-López M, Beltrán-Debón R, Borrás-Linares I, Barrajón-Catalán E, Joven J, Fernández-Gutiérrez A, Segura-Carretero A, Micol V. Source Department of Analytical Chemistry, Faculty of Sciences, University of Granada, Av. Fuentenueva, Granada, Spain. Abstract The aqueous extracts of Hibiscus sabdariffa have been commonly used in folk medicine. Nevertheless, the compounds or metabolites responsible for its healthy effects have not yet been identified. The major metabolites present in rat plasma after acute ingestion of a polyphenol-enriched Hibiscussabdariffa extract were characterized and quantified in order to study their bioavailability. The antioxidant status of the plasma samples was also measured through several complementary antioxidant techniques. High-performance liquid chromatography coupled to time-of-flight mass spectrometry (HPLC-ESI-TOF-MS) was used for the […]

1 10, 2012
  • Permalink Gallery

    The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.

The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.

By |October 1st, 2012|Publicacions|0 Comments|

Aragonès G, Pardo-Reche P, Fernández-Sender L, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Camps J, Joven J, Alonso-Villaverde C.

Source
Unitat de Recerca Biomèdica, Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain.

Abstract

We investigated the potential differential effects of antiretroviral therapies on unbalanced chemokine homeostasis and on the progression ofatherosclerosis in HIV-infected patients. A two-year prospective study was performed in 67 consecutive HIV-infected patients initiating antiretroviral therapy with abacavir/lamivudine or tenofovir/emtricitabine. Circulating levels of inflammatory biomarkers, progression of subclinical atherosclerosisand expression levels of selected chemokines genes in circulating leukocytes were assessed. Control subjects showed significantly lower plasma concentrations of CRP, tPA, IL-6, and MCP-1 than HIV-infected patients at a baseline. After two years of followup, the observed decreases in plasma inflammatory biomarker levels were only significant for MCP-1, tPA, and IL-6. The decrease in plasma MCP-1 concentration was associated with […]

1 10, 2012
  • Permalink Gallery

    The level of DING proteins is increased in HIV-infected patients: in vitro and in vivo studies.

The level of DING proteins is increased in HIV-infected patients: in vitro and in vivo studies.

By |October 1st, 2012|Publicacions|0 Comments|

Djeghader A, Aragonès G, Darbinian N, Elias M, Gonzalez D, García-Heredia A, Beltrán-Debón R, Kaminski R, Gotthard G, Hiblot J, Rull A, Rohr O, Schwartz C,Alonso-Villaverde C, Joven J, Camps J, Chabriere E.

Source
Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Centre National de la Recherche Scientifique, Faculté de Médecine Aix-Marseille University, Marseille, France.

Abstract

DING proteins constitute an interesting family, owing to their intriguing and important activities. However, after a decade of research, little is known about these proteins. In humans, at least five different DING proteins have been identified, which were implicated in important biological processes and diseases, including HIV. Indeed, recent data from different research groups have highlighted the anti-HIV activity of some DING representatives. These proteins share the ability to inhibit the transcriptional step of HIV-1, a key step of the viral cycle that is not yet targeted by the current […]

1 10, 2012
  • Permalink Gallery

    Human Duffy blood group alloantigen system influences the measurement of monocyte chemoattractant protein-1 (MCP-1) in serum but not in plasma

Human Duffy blood group alloantigen system influences the measurement of monocyte chemoattractant protein-1 (MCP-1) in serum but not in plasma

By |October 1st, 2012|Publicacions|0 Comments|

Aragonès G, Ercilla A, Barreda M, Rull A, Beltrán-Debón R, Rodríguez-Gallego E, Alonso-Villaverde C, Camps J, Joven J.

Source
Centre de Recerca Biomèdica, Universitat Rovira i Virgili, Hospital Universitari de Sant Joan, IISPV, Reus, Spain.

Abstract

BACKGROUND:
We explored whether the Asp42Gly polymorphism (rs12075) in the DARC gene represents a confounding factor in the interpretation of monocyte chemoattractant protein-1 (MCP-1) concentration in circulating blood.
METHODS:
MCP-1 concentration in serum and plasma were measured in 278 healthy Caucasian participants who are representative of our geographic area. The rs12075 genotype distribution was also assessed in this population.
RESULTS:
Plasma MCP-1 concentration did not vary among the rs12075 polymorphism derived genotypes [in pg/mL, AA: 171.9 (100.2 – 287.2), AG: 178.9 (105.1 – 326.4) and GG: 173.7 (94.4 – 405.7)]. However, there were significant increases in serum MCP-1 related to the presence of the A allele [in pg/mL, AA: 334.6 (180.4 – 756.4), AG: 299.1 […]